FcRn 阻断还限制了类似 IgG 介导的 EAE 多发性硬化症(MG)模型中的视运动缺陷，减少了脊髓脱髓鞘，并特别改变了巨噬细胞对脊髓的浸润，而 B 细胞、T 细胞或补体沉积没有差异。

2023年8月23日 · FcRn receptor inhibitors demonstrate efficacy across diverse subgroups and a wide range of MG severity, supported by robust clinical evidence. Efgartigimod has been approved in the management of gMG, rozanolixizumab is under review by health authorities, and there are phase 3 trials ongoing for nipocalimab and batoclimab.

In rodent models of MG, primary immune thrombocytopenic purpura (ITP), experimental autoimmune encephalomyelitis (EAE), epidermolysis bullosa acquisita, and arthritis, anti-FcRn antibodies can effectively reduce plasma concentrations of pathogenic IgG and exert beneficial effects on disease symptoms (Smith et al., 2019; Kasprick et al., 2020 ...

Therapeutic platforms targeting Fc-mediated functions through classical FcγRs and the non-classical major histocompatibility complex (MHC) class I-related neonatal FcR (FcRn), which regulates IgG serum half-life, are currently being developed, tested in clinical trials or have been successfully translated into the clinic for the benefit of ...

2024年10月23日 · FcRn抑制剂在MG治疗中展现出了良好的症状改善效果以及安全性，其中罗泽利昔珠单抗作为目前国际获批用于治疗MuSK阳性MG的药物，对MG多维度的评分均有快速、显著的改善效果，长期使用可持续稳定改善症状，在多个治疗周期中的应答率高，同时具有良好的安全 ...

2023年8月4日 · FcRn receptors prevent the catabolism of IgG by impeding their lysosomal degradation and facilitating their extracellular release at physiological pH, consequently extending the IgG half-life.

免疫治疗已成为MG的重要治疗方法，其中新生儿Fc受体(FcRn)拮抗剂作为一种全新靶向免疫治疗药物，通过与免疫球蛋白(IgG)竞争性结合FcRn而加速清除致病性IgG，在临床实践中治疗乙酰胆碱受体抗体(AChR-ab)阳性成人全身型重症肌无力(gMG)显示出良好的疗效和安全性。

2024年5月9日 · Neonatal Fc receptor-targeted therapies are engineered to selectively target FcRn through various methods, such as Fc fragments or monoclonal anti-FcRn antibodies. These approaches enhance the breakdown of autoantibodies by blocking the immunoglobulin G recycling pathway.

2024年3月3日 · FcRn inhibitors have good efficacy and safety in patients with MG. Among them, efgartigimod and nipocalimab were effective without causing an increased safety risk. Rozanolixizumab, despite its superior efficacy, caused an increased incidence of adverse events.

2020年1月9日 · A high affinity, pH-independent rat anti-FcRN inhibitor enhanced the clearance of pathogenic AChR antibodies and demonstrated a dose-dependent improvement in disease symptoms in both passive and active models of induced autoimmune MG. Therapeutic potential for FcRn agents was also demonstrated in a mouse model for muscle-specific kinase (MuSK ...